BRAF wild-type metastatic colorectal cancer patients

Overview of attention for article published in Frontiers in oncology, February 2023

Altmetric Badge

Mentioned by

twitter: 2 X users

Readers on

mendeley: 11 Mendeley

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 23,814 followers.

Efficacy of third-line anti-EGFR-based treatment versus regorafenib or trifluridine/tipiracil according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients https://t.co/k5DKObLYQ8 https://t.co/wRxQcL0eZK

27 Feb 2023

Reply Repost Favourite

New research: Efficacy of third-line anti-EGFR-based treatment versus regorafenib or trifluridine/tipiracil according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients: Background Right- (R) and left-sided (L)… https://t.co

23 Feb 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.